Skip to main page content (V体育安卓版)
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2018 Jan 31;35(3):25.
doi: 10.1007/s12032-018-1080-0.

The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma

Anton Uryvaev  1 , Maria Passhak  1 , Dov Hershkovits  2 , Edmond Sabo  3   4 , Gil Bar-Sela  5   6   7
Affiliations

The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma

Anton Uryvaev et al. Med Oncol. .

Abstract

Immunotherapy plays an important role in cancer treatment. Biomarkers that can predict response, including tumor-infiltrating lymphocytes (TILs), are in the spotlight of many studies. This cohort study was designed to evaluate the role of CD4+ and CD8+ TILs as predictive factors for response to anti PD-1 treatment in patients with metastatic non-small cell lung cancer (NSCLC) or metastatic melanoma. We evaluated the expression of CD4+ and CD8+ TILs in tissue samples of 56 patients with metastatic NSCLC or melanoma treated with anti-PD1 immunotherapy. The study included 30 patients with melanoma and 26 with NSCLC. An association was found between CD8+/CD4+ TILs ratio and response to anti-PD1 treatment in both cancers. Regarding melanoma patients, ratios of CD8+/CD4+ lower than 2 predicted lack of response to treatment (0%) (p = 0. 006), while CD8+/CD4+ ratios higher than 2 VSports手机版. 7 had an 81. 3% response rate (p = 0. 0001). In addition, we found that the presence of more than 1900/mm2 of CD8+ lymphocytes in the melanoma tumor predicted a 90% response to therapy. In the metastatic NSCLC group, tumors with CD8+ lymphocyte count under 886/mm2 showed low response rates (16. 7%, p = 0. 046). When the CD8+ lymphocyte count was in the range of 886-1899/mm2, the response rate was high (60%, p = 0. 017). In CD8+/CD4+ ratios lower than 2, the response rate was low (13. 3%), and in ratios higher than 2, response rates ranged between 43 and 50% (p = 0. 035). The use of CD8+/CD4+ TILs ratios in tumor biopsies may predict response to anti-PD1 treatment in metastatic melanoma and NSCLC. .

Keywords: CD4+ lymphocyte; CD8+ lymphocyte; Lung cancer; Melanoma; Tumor-infiltrating lymphocytes (TILs). V体育安卓版.

PubMed Disclaimer

References

    1. Clin Cancer Res. 2004 Jan 15;10(2):521-30 - "VSports" PubMed
    1. Cancer. 2008 Sep 15;113(6):1387-95 - "V体育2025版" PubMed
    1. Lancet. 2016 Apr 9;387(10027):1540-1550 - PubMed
    1. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
    1. Cancer Biol Med. 2015 Jun;12(2):74-8 - PubMed

MeSH terms (V体育平台登录)